At the 22nd Annual Conference of the National Comprehensive Cancer Network, held March 23-25, 2017, in Orlando, FL, Gregory J. Riely, MD, PhD, Memorial Sloan Kettering Cancer Center, spoke about the what, when, and how of biomarker testing in non-small cell lung cancer.
At the 22nd Annual Conference of the National Comprehensive Cancer Network (NCCN), held March 23-25, 2017, in Orlando, Florida, Gregory J. Riely, MD, PhD, Memorial Sloan Kettering Cancer Center, spoke about the what, when, and how of biomarker testing in non-small cell lung cancer.
Biomarker testing is essential in lung cancer, Riely said, and should be done at diagnosis. “Even if it is not done at diagnosis, testing before the choice of second-line therapy is valuable as well.”
Riley showed the scanned image of the lungs of a woman who presented with an adenocarcinoma. Diagnosis of an adenocarcinoma may not be as bad as it was a decade ago, he said, adding, “We need to identify biomarkers for this, which, today, can start with molecular analysis and PD-L1 testing.”
Based on the results of the molecular analysis, the patient may receive:
“Current NCCN Guidelines for a patient who presents with metastatic disease recommend molecular testing to establish histologic subtype, smoking cessation counseling, and palliative care. For all the various histological subtypes, molecular testing is central,” Riley said. The key thing is to conduct these tests as part of a broad molecular testing profile. An important consideration is multiplexing to be able to maximize on the small biopsy sample.
fluorescence in situ hybridization, known as FISH
Molecular testing for lung cancer has focused on DNA-based tests like sequencing and . But over the last few years, protein tests have grown in usage, primarily immunohistochemistry.
Riley then shared phase 3 results from the KEYNOTE-024 trial that were presented at the annual meeting of the European Society for Medical Oncology last year and published in the New England Journal of Medicine, which showed that pembrolizumab was effective in advanced lung cancer, compared with platinum-based chemotherapy, when PD-L1 was expressed in at least 50% of tumor cells.
“However, PD-L1 tests are all over the map, so how do you choose?” asked Riley. The fact that each PD-1 inhibitor introduced and approved has developed a complementary assay to test PD-L1 expression in the tumor samples makes it challenging to figure out how all these tests compare.
A recently published study in JAMA Oncology compared 4 such PD-L1 assays, and found that while the tests were analytically interchangeable, they had not been cross validated. Further, only 3 of the 4 assays were concordant and reproducible.
An important point that Riley noted during his presentation was that PD-L1 expression is probably stable and there is no clear benefit to repeat a biopsy unless the prior sample is exhausted.
It’s also important, to customize biomarker testing needs based on the institution.
“Often, institutions use a combination of tactics to achieve comprehensive evaluation in a timely manner,” Riley said.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
New Strategy Shows Promise for CD7-Positive Leukemia/Lymphoma
May 9th 2024This study introduces a novel "all-in-one" strategy combining CD7 chimeric antigen receptor T-cell therapy with haploidentical hematopoietic stem-cell transplantation, showing significant potential to improve survival and reduce toxicities in patients with relapsed or refractory CD7-positive hematologic cancers.
Read More